HIV cell therapy biotech Addimmune to go public via SPAC merger; WHO names new Covid-19 'variant of interest' End Points, 10 Aug 2023 Addimmune, a biotech that is working on a cell therapy for HIV, announced Wednesday that it plans to merge with 10X Capital…